Duloxetine Capsule, Delayed Release
Product Images NDC 70518-2630

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-2630). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine 60mg 70518 2630 01

Duloxetine 60 mg delayed-release capsule label showing quantity of 30 capsules. The label includes the NDC number 70518-2630-01, manufacturing information from Ajanta Pharma Ltd. in India, and repackaging details by RemedyRepack Inc. Dosage instructions refer to the package insert, and storage temperature guidelines are provided.*

FDA Label Image

Duloxetine 60mg 70518 2630 02

Duloxetine 60 mg delayed-release capsule label showing a quantity of 90 capsules. The label includes directions to see the package insert, storage temperature instructions, and indicates repackaging by RemedyRepack Inc. Manufacturing is noted from Ajanta Pharma Ltd., Paithan, India. The label shows the NDC 70518-2630-02 with placeholders for expiration and lot number.*

FDA Label Image

Remedy_label (Remedy Label)

Duloxetine 60 mg delayed-release capsules packaging label indicating a quantity of 60 capsules. The label shows the product NDC 70518-2630-00, manufacturer Ajanta Pharma Ltd., and repackager RemedyRepack Inc. It includes directions to see the package insert and storage instructions with temperature ranges. The label features the RemedyRepack logo and states RX ONLY.*

FDA Label Image

Duloxetine Fig1

A Kaplan-Meier curve chart comparing the proportion of patients experiencing relapse over time (in days) between Duloxetine and placebo treatments. The x-axis represents time from randomization to relapse, and the y-axis shows the proportion of patients with relapse. Duloxetine shows a lower relapse proportion over time compared to placebo.*

FDA Label Image

Duloxetine Fig10

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo and Duloxetine 60/120 mg once daily, showing higher patient improvement percentages with Duloxetine across increasing pain improvement thresholds.*

FDA Label Image

Duloxetine Fig2

A line graph comparing the proportion of patients with relapse over time from randomization (in days) between Duloxetine and placebo treatments. The x-axis shows time in days up to 300, and the y-axis shows the proportion of patients with relapse ranging from 0.0 to 1.0. The graph includes a legend identifying Duloxetine with a solid line and placebo with a dashed line.*

FDA Label Image

Duloxetine Fig3

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four groups are compared: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, each represented by different markers. The graph shows higher percentages of patients improved with Duloxetine doses compared to placebo across increasing pain improvement percentages.*

FDA Label Image

Duloxetine Fig4

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The y-axis represents the percentage of patients improved, and the x-axis represents the percent improvement in pain from baseline.*

FDA Label Image

Duloxetine Fig5

A line graph showing the percentage of patients improved against percent improvement in pain from baseline. Three data series are plotted: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, illustrating their comparative effectiveness in pain improvement over a range of percent improvement values.*

FDA Label Image

Duloxetine Fig6

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, 20 mg once daily, and a placebo. The graph shows data trends for these four groups, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Duloxetine Fig8

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis indicates percent improvement in pain from 0% to 100%, and the y-axis shows the percentage of patients improved from 0% to 100%. Duloxetine consistently shows higher patient improvement percentages across most pain improvement intervals compared to placebo.*

FDA Label Image

Duloxetine Fig9

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows increasing percent improvement in pain, while the y-axis shows the percentage of patients improved. Two lines represent Duloxetine and placebo, with Duloxetine consistently showing higher percentages across increasing pain improvement thresholds.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride showing its molecular composition and arrangement in a two-dimensional diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.